GlucoTrack (GCTK) Competitors $1.74 +0.06 (+3.57%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends GCTK vs. PAVM, BSGM, MBOT, XAIR, CODX, ALUR, SURG, STIM, DRIO, and FEMYShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include PAVmed (PAVM), BioSig Technologies (BSGM), Microbot Medical (MBOT), Beyond Air (XAIR), Co-Diagnostics (CODX), Allurion Technologies (ALUR), SurgePays (SURG), Neuronetics (STIM), DarioHealth (DRIO), and Femasys (FEMY). These companies are all part of the "medical equipment" industry. GlucoTrack vs. PAVmed BioSig Technologies Microbot Medical Beyond Air Co-Diagnostics Allurion Technologies SurgePays Neuronetics DarioHealth Femasys PAVmed (NASDAQ:PAVM) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Does the MarketBeat Community believe in PAVM or GCTK? PAVmed received 202 more outperform votes than GlucoTrack when rated by MarketBeat users. CompanyUnderperformOutperformPAVmedOutperform Votes20266.01% Underperform Votes10433.99% GlucoTrackN/AN/A Which has preferable valuation and earnings, PAVM or GCTK? GlucoTrack has lower revenue, but higher earnings than PAVmed. GlucoTrack is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$3.83M2.79-$64.18M-$8.19-0.13GlucoTrackN/AN/A-$7.10M-$2.42-0.72 Is PAVM or GCTK more profitable? GlucoTrack has a net margin of 0.00% compared to PAVmed's net margin of -1,508.12%. PAVmed's return on equity of 0.00% beat GlucoTrack's return on equity.Company Net Margins Return on Equity Return on Assets PAVmed-1,508.12% N/A -102.44% GlucoTrack N/A -826.43%-325.85% Do institutionals & insiders have more ownership in PAVM or GCTK? 19.9% of PAVmed shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 14.7% of PAVmed shares are held by insiders. Comparatively, 6.3% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer PAVM or GCTK? In the previous week, PAVmed had 2 more articles in the media than GlucoTrack. MarketBeat recorded 2 mentions for PAVmed and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.00 beat PAVmed's score of 0.80 indicating that GlucoTrack is being referred to more favorably in the news media. Company Overall Sentiment PAVmed Positive GlucoTrack Positive Which has more volatility and risk, PAVM or GCTK? PAVmed has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Do analysts rate PAVM or GCTK? PAVmed presently has a consensus target price of $21.00, indicating a potential upside of 1,944.79%. Given PAVmed's higher possible upside, equities research analysts clearly believe PAVmed is more favorable than GlucoTrack.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50GlucoTrack 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryPAVmed beats GlucoTrack on 12 of the 16 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.54M$4.41B$5.50B$8.53BDividend YieldN/A42.37%5.13%4.14%P/E Ratio-0.7239.21116.1015.23Price / SalesN/A64.601,496.2597.74Price / CashN/A49.0939.7434.10Price / Book2.264.264.775.07Net Income-$7.10M$11.52M$119.06M$225.46M7 Day Performance-1.14%1.06%0.80%0.37%1 Month Performance-22.67%0.92%5.65%3.57%1 Year Performance93.33%39.37%36.75%29.43% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack0.306 of 5 stars$1.74+3.6%N/A+98.9%$9.54MN/A-0.725Short Interest ↓Gap UpPAVMPAVmed4.1617 of 5 stars$1.07+7.0%$21.00+1,862.6%-73.0%$11.14M$2.45M-0.1390Positive NewsBSGMBioSig TechnologiesN/A$0.87+6.1%N/A-75.9%$12.32M$40,000.000.0050Gap DownMBOTMicrobot Medical2.2548 of 5 stars$0.98+2.1%$7.00+616.6%-20.2%$15.60MN/A-1.2120News CoverageXAIRBeyond Air4.5283 of 5 stars$0.40+2.6%$3.67+812.3%-79.0%$18.45M$1.78M-0.2570Gap UpCODXCo-Diagnostics3.2307 of 5 stars$1.23-0.8%$1.50+22.0%+13.1%$38.47M$9.14M-0.98100Upcoming EarningsShort Interest ↑ALURAllurion Technologies1.8825 of 5 stars$0.76+5.6%$2.88+278.2%-83.9%$36.45M$47.59M-0.86501Gap UpSURGSurgePays3.6214 of 5 stars$1.74+0.6%$9.00+417.2%-64.2%$34.37M$137.14M19.3422News CoverageSTIMNeuronetics2.5974 of 5 stars$0.99+2.1%$4.67+371.4%-10.4%$29.70M$72.07M-0.88180Upcoming EarningsNews CoverageDRIODarioHealth2.1152 of 5 stars$0.97+3.2%$4.00+312.4%-6.2%$29.03M$19.15M-0.82200Upcoming EarningsFEMYFemasys3.4353 of 5 stars$1.27+5.8%$10.67+739.9%-9.4%$28.68M$1.07M-1.5330Analyst ForecastNews Coverage Related Companies and Tools Related Companies PAVM Alternatives BSGM Alternatives MBOT Alternatives XAIR Alternatives CODX Alternatives ALUR Alternatives SURG Alternatives STIM Alternatives DRIO Alternatives FEMY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GCTK) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GCTK Stock Alerts